RecruitingPhase 2NCT03498326

Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University

Enrollment

480 participants

Start Date

Apr 2, 2018

Study Type

INTERVENTIONAL

Conditions

Pancreatic Cancer Chemotherapy Effect

Summary

The prognosis of pancreatic cancer is extremely poor, even in those patients who had underwent surgery, the 5-year survival is still less than 10%. Current guidelines recommend Gemcitabine monotherapy for R0 resection of pancreatic cancer. Inflammation plays an critical role in the development and progression of pancreatic cancer. Here we intend to assess the synergistic effect of using celecoxib in combination with gemcitabine on the treatment of R0 resection of pancreatic cancer.

Eligibility

Min Age: 18 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This trial is studying whether combining two cancer drugs — gemcitabine (a chemotherapy) and celecoxib (an anti-inflammatory medication) — can help prevent pancreatic cancer from coming back after surgery. **You may be eligible if...** - You are 18 years or older - You had surgery that completely removed your pancreatic tumor (called R0 resection) - You have not previously received gemcitabine for any cancer treatment - Your general health allows you to be somewhat active (ECOG score 0–2) - Your blood counts, liver function, and kidney function are within acceptable ranges **You may NOT be eligible if...** - Your cancer is a special type of pancreatic tumor (endocrine carcinoma, acinar carcinoma, or cystadenocarcinoma) - Your surgery did not completely remove the tumor - You have had prior chemotherapy with gemcitabine Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGemcitabine

One group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2.

DRUGGemcitabine

the other group patients receive the standard gemcitabine treatment at 1,8,15 of the chemotherapy cycle after R0 resection at 1000mg/m2, and receive additional celecoxib 200mg bid every days during chemotherapy period.

Locations(1)

the second affiliated hospital of Zhejiang University

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03498326

Related Trials

DESTINY-PANTUMOUR04

NCT0712400017 locations

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

NCT0725223217 locations

In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers

NCT072063551 location

Incremental Value of Magnetic Resonance Imaging in Selection of Pancreatic Cancer Patients for Surgery

NCT054283583 locations

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT028388361 location